Anti-leukotriene agents: A new direction in asthma therapy

Journal of Asthma

Volumn 33, Issue 6, 1996, Pages 353-366

  Nathan, Robert A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Asthma & Allergy Associates PC and Research Center   (United States)

Author keywords

5 lipoxygenase inhibitors; Asthma; Inflammation; Inflammatory mediators; Leukotriene receptor antagonists; Leukotrienes

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; TOMELUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; EOSINOPHIL; LUNG; LUNG FUNCTION; MUCUS SECRETION; REVIEW;

EID: 0030445953     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770909609068181     Document Type: Review

References (95)

1. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA: State of the art: Bronchial hyperreactivity. Am Rev Respir Dis 121:389-413 (1980).
2. Beasley R, Roche WR, Roberts JA, Holgate ST: Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 139:806-817 (1989).
3. Samuelsson B: Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575 (1983).
4. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, Corey EL: Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 77:4345-4358 (1980).
5. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M: Slow-reacting substances, leukotriene C4 and D4 increase the release of mucus from human airways. Am Rev Respir Dis 126:449-451 (1982).
6. Barnes NC, Piper PJ, Costello JF: Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 39:500-504 (1984).
7. 4 in the blood of asthmatic children. Biochem Biophys Res Commun 130:486-492 (1985).
8. Okubo T, Takahashi H, Sumitomo M, Shindoh K, Suzuki S: Plasma levels of leukotriene C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol 54:149-155 (1987).
9. Proceedings of workshop panel of a WHO meeting. The prevention of allergic diseases. Clin Allergy 16(Suppl 1):1-60 (1986).
10. Sly RM: Changing asthma mortality and sales of inhaled bronchodilators and antiasthmatic drugs. Ann Allergy 73:439-443 (1994).
11. Sly RM: Changing asthma mortality. Ann Allergy 73:259-268 (1994).
12. Arrighi HM: US asthma mortality: 1941 to 1989. Ann Allergy Asthma Immunol 74:321-326 (1995).
13. Larsen GL: The late asthmatic response. Chest 93: 1287-1289 (1988).
14. O'Byrne PM, Dolovich J, Hargreave FE: State of the art: Late asthmatic responses. Am Rev Respir Dis 136:740-751 (1987).
15. Schleimer RP, MacGlashan DW Jr, Peters SP, Pinckard RN, Adkinson NF Jr, Lichtenstein LM: Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 133:614-617 (1986).
16. MacGlashan DW Jr, Schleimer RP, Peters SP, Schulman ES, Adams GK III, Newball HH, Lichtenstein LM: Generation of leukotrienes by purified human lung mast cells. J Clin Invest 70:747-751 (1982).
17. De Monchy JGR, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, De Vries K: Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 183:373-376 (1985).
18. Wegner CD, Gundel RH, Reilly P, Haynes N, Letts LG, Rothlein R: Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 247:456-459 (1990).
19. Gleich GJ, Flavahan NA, Fujisawa T, Vanhoutte PM: The eosinophilas a mediator of damage to respiratory epithelium: A model for bronchial reactivity. J Allergy Clin Immunol 81:776-781 (1988).
20. Horn RB, Robin ED, Theodore J, Van Kessel A: Total eosinophil counts in the management of bronchial asthma. N Engl J Med 292:1152-1155 (1975).
21. Bousquet J, Chanez D, Lacoste JY, Barneou G, Ghavanian N, Enhander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel F-B: Eosinophilic inflammation in asthma. N Engl J Med 323:1033-1039 (1990).
22. Calhoun WJ, Sedgwick J, Busse WW: The role of eosinophils in the pathophysiology of asthma. Ann NY Acad Sci 629:62-72 (1991).
23. Taniguchi N, Mita H, Saito H, Yui Y, Kajita T, Shida T: Increased generation of leukotriene C4 from eosinophils in asthmatic patients. Allergy 40:571-573 (1985).
24. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH: Leukotriene E4 and granulocy tic infiltration into asthmatic airways. Lancet 341:989-990 (1993).
25. Spada CS, Nieves AL, Krauss AH-P, Woodward DF: Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leuko Biol 55:183-191 (1994).
26. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304 (1992).
27. Barnes PJ. Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 150:S42-S49 (1994).
28. Hogg JC: Pathology of asthma. J Allergy Clin Immunol 92:1-5(1993).
29. National Asthma Education Program, Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health Publication No. 91-3042, 1991.
30. Global Initiative for Asthma. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NHLBI. Publication No. 95-3659, January 1995.
31. Rand CS, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, Li VC, Tashkin DP: Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 746:1559-1564 (1992).
32. Rand CS, Nides M, Cowles MK, Wise RA, Connett J: Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 152:580-588 (1995).
33. McFadden ER Jr: The β-agonist controversy revisited. Ann Allergy Asthma Immunol 75:173-176 (1995).
34. Andersson KE, Persson KE: Extrapulmonary effects of theophylline. Eur J Respir Dis 61:17-28 (1980).
35. Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med 98:196-208 (1995).
36. Doull IJM, Freezer NJ, Holgate ST: Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 151:1715-1719 (1995).
37. Samuelsson B, Borgeat P, Hammarstrom S, Murphy RC: Introduction of a nomenclature: Leukotrienes. Prostaglandins 17:785-787 (1979).
38. Brocklehurst WE: The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 151:416-435 (1960).
39. Samuelsson B, Dahlen SE, Lmdgren JA, Ronzer CA, Serhan CN: Leukotrienes and lipoxis: Structures, biosynthesis and biological effects. Science 237:1171-1176 (1987).
40. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW: MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 265:1436-1442 (1990).
41. Haeggstrom JZ, Wetterholm A, Shapiro R, Vallee BL, Samuelsson B: Leukotriene A4 hydrolase: A zinc metalloenzyme. Biochem Biophys Res Commun 372:965-970 (1990).
42. Nicholson DW, Ali A, Klemba MW, Munday NA, Zamboni RJ, Ford-Hutchinson AW: Human leukotriene C4 synthase expression in dimethyl sulfoxide differentiated U937 cells. J Biol Chem 267: 17849-17857 (1992).
43. Welsch DJ, Creely DP, Mathis KJ, Hauser SD, Isakson PC: Molecular cloning and expression of human leukotriene C4 synthase. Adv Prost Throm Leuko Res 23: 167-169 (1995).
44. Lam BK, Owen WF Jr, Austen KF, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 264-12885-12889 (1989).
45. Lam BK, Gagnon L, Austen KF, Soberman RJ: The mechanism of leukotriene B4 export from human polymorphonuclear leukocytes. J Biol Chem 265: 13438-13441 (1990).
46. Verhagen J, Bel EH, Kijne GM, Sterk PJ, Bruynzeel PCB, Veldink GA, Vliegenthart JFC: The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals. Biochem Biophys Res Commun 148:864-868 (1987).
47. Taylor GW, Taylor I, Black P, Maltby NH, et al: Urinary leukotriene E4 after antigen challenge in acute asthma and allergic rhinitis. Lancet 1:584-588 (1989).
48. Drazen JM, O'Brien J, Sparrow D, Weiss ST, Martins MA: Recovery of leukotriene E4 from the urine of patients with airways obstruction. Am Rev Respir Dis 146:104-108 (1992).
49. Taylor IK, Taylor GW, Fuller RW: Platelet activating factor (PAF)-induced bronchoconstriction in asthmatics. Role of cysteinyl-leukotrienes. Thorax 450-790 (1990)
50. 4 and histamine in athmatics. Am Rev Respir Dis 246:96-103 (1992).
51. Lam S, Chan H, Le Riche JC, Chan-Yeung M, Salari H: Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 81:711-717 (1988).
52. Nicosia S, Capra V, Ragnini D, Giovanazzi S, Mezzetti M, Keppler D, Muller M, Rovati GE: Receptors for cys-leukotrienes in human lung parenchyma: Characterization by computer modelling and photoaffinity labelling of binding sites. Adv Prost Throm Leuko Res 23:267-269 (1995).
53. Snyder DW, Krell RD: Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther 235:616-622 (1984).
54. 4. J Pharmacol Exp Ther 237:558-562 (1986).
55. Drazen J: Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 524:289-297 (1988).
56. Rovati GE, Giovanazzi S, Mezzetti M, Nicosia S: Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol 44:1411-1415 (1992).
57. Drazen J: Leukotrienes. In Asthma and Rhinitis (Busse WW, Holgate ST, editors). Blackwell Scientific Publications, Oxford, UK, 1995, 838-850.
58. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, Dahlen SE, Drazen JM, Gardiner PJ, Jackson WT, Jones TR, Krell RD, Nicosia S: Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature. Adv Prost Throm Leuko Res 23:283-285 (1995).
59. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH: Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264-265 (1980).
60. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M: The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest 81:365-370 (1982).
61. Cohen N, Yagaloff KA: Recent progress in the development of leukotriene B4 antagonists. Curr Opin Invest Drugs 3:13-22 (1994).
62. Barnes NC, Piper PJ, Costello JF: Hyperresponsiveness of asthmatics to inhaled leukotriene D4. Am Rev Respir Dis 131:A24 (1985).
63. 4 in atopic subjects J Allergy Clin Immunol 53:939-944 (1989).
64. Smith LJ, Glass MG, Minkwitz MC: Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI-204,219. Clin Pharmacol Ther 54:430-436 (1993).
65. Bernstein JA, Greenberger PA, Patterson R, Glass M, Krell R, Thyrum PT: The effect of the oral leukotriene antagonist, ICI-204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man. J Allergy Clin Immunol 87:93-98 (1991).
66. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST: Role of leukotrienes in exercise-induced asthma: Inhibitory effect of ICI 204,219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 145:746-749 (1992).
67. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST: The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 147:1413-1418 (1993).
68. O'Shaughnessy KM, Taylor IK, O'Connor B, O'Connell F, Thomson H, Dollery CT: Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 147:1431-1435 (1993).
69. Nathan RA, Glass M, Minkwitz MC: Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 105:483-488 (1994).
70. Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE: The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 7:324-331 (1994).
71. Findlay SR, Barden JM, Easley CB, Glass M: Effect of the oral leukotriene antagonist ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 59:1040-1045 (1992).
72. Spector SL, Smith LJ, Glass M, the Accolate Asthma Trialists Group: Effect of 6 weeks of therapy with oral doses of ICI-204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. J Respir Crit Care Med 150:618-623 (1994).
73. Donnelly AL, Glass M, Minkwitz MC, CasaleTB: The leukotriene D4-receptor antagonist, ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 151:1734-1739 (1995).
74. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y: Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 150: 254-257 (1994).
75. Tariguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, Takishima T: The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 92:507-512 (1993).
76. Grossman J, Bronsky E, Busse W, Montanaro A, Southern L, Tinkelman D, Dubb J, Faiferman I: A multicenter, double-blind, placebo-controlled study to evaluate the safety, tolernbility and clinical activity of oral, twice-daily LTA, pranlukast (SB 205312) in patients with mild to moderate asthma. J Allergy Clin Immunol 95:352 (1995).
77. 4 receptor antagonist exhibits a dose response in the inhibition of exercise induced bronchoconstriction at the end of a once daily dosing interval. J Invest Med 43:275A (1995).
78. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz J, O'Byrne P: Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist. N Engl J Med 323: 1736-1739 (1990).
79. Hendeles L, Davison D, Blake K, Harman E, Cooper R, Margolskee D: Leukotriene D4 is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific leukotriene D4 receptor antagonist. J Allergy Clin Immunol 8:197 (1990).
80. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE: Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 48:1205-1210 (1993).
81. Rasmussen JB, Eriksson LO, Tagari P, Stahl KG, Andersson KE: Reduced nonspecific bronchial reactivity and airway response to antigen in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L648,051. Allergy 47:604-609 (1992).
82. Rosenthal R, Lavins BJ, Hanby LA: Effect of treatment with zafirlukast (Accolate) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma. J Allergy Clin Immunol 97:250 (1996).
83. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, Barnes PJ: Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 46:184-189 (1991).
84. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM: The pivotal role of 5-lipoxygenase products in the reaction of aspirin sensitive asthmatics to aspirin. Am Rev Respir Dis 143:1447-1451 (1993).
85. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 719:1059-1066 (1993).
86. Israel I, Cohn J, Dube L, Drazen JM, Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial. JAMA 275(12):931-936 (1996).
87. Kane GC, Pollice M, Kim C-J, Cohn J, Dworski RT, Murray JJ, Sheller JR, Fish JE, Peters SP: A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 97:646-654 (1996).
88. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY: Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 152:897-905 (1995).
89. Nasser SMS, Bell GS, Foster S, Spruce KE, MacMillan R, Williams AJ, Lee TH, Arm JP: Effect of the 5-lipoxygenase inhibitor ZD 2138 on aspirin-induced asthma. Thorax 49:749-756 (1994)
90. Nasser SMS, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, Lee TH, Arm JP: Effect of the 5-lipoxygenase inhibitor ZD 2138 on allergen-induced early and late asthmatic responses. Thorax 49: 743-748 (1994).
91. Meltzer SS, Johns MA, Rechsteiner EA, Jungerwirth S, D'Amico JM, Bleecker ER: Bronchodilatory effects of BAY 1005, a 5-lipoxygenase inhibitor, in mild to moderate asthma. J Allergy Clin Immunol 93:294 (1994).
92. Virchow JC, Noller PS, Weibmann KJ, Buhl R, Thalhofer S, Dorow G, Kunkel G, Ukena D, Ulbrich E, Sybrecht G, Matthys H: Multicenter trial of BAY X 1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma. Am J Respir Crit Care Med 151(4 part 2):A377 (1995).
93. O'Byrne PM, Watson RM, Strong HA, Wyile G: The effect of treatment with a 5-lipoxygenase inhibitor, BAYx 1005 on allergen-induced asthmatic responses in human subjects. Am J Respir Crit Care Med 149: A532 (1994).
94. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han Y-HR, Shingo S, Spector R, Sterk P: Oral leukotriene inhibitor (MK 886) blocks allergen-induced airway responses. Am Rev Respir Dis 147:839-844 (1993).
95. Diamant Z, Timmers MC, van der Veen H, Friedman BS, De Smet M, Depre M, Hilliard D, Bel EH, Sterk PJ: The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 95:42-51 (1995).